Beraprost

Beraprost
Systematic (IUPAC) name
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4- methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran- 5-butanoic acid
Identifiers
CAS number	88430-50-6 88475-69-8 (sodium salt)
ATC code	B01AC19
PubChem	5282428
Chemical data
Formula	C24H30O5
Mol. mass	398.492 g/mol
Pharmacokinetic data
Bioavailability	50–70%
Metabolism	Unknown
Half life	35–40 minutes
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	?
Routes	Oral

WikiDoc Resources for Beraprost
Articles
Most recent articles on Beraprost Most cited articles on Beraprost Review articles on Beraprost Articles on Beraprost in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Beraprost Images of Beraprost Photos of Beraprost Podcasts & MP3s on Beraprost Videos on Beraprost
Evidence Based Medicine
Cochrane Collaboration on Beraprost Bandolier on Beraprost TRIP on Beraprost
Clinical Trials
Ongoing Trials on Beraprost at Clinical Trials.gov Trial results on Beraprost Clinical Trials on Beraprost at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Beraprost NICE Guidance on Beraprost NHS PRODIGY Guidance FDA on Beraprost CDC on Beraprost
Books
Books on Beraprost
News
Beraprost in the news Be alerted to news on Beraprost News trends on Beraprost
Commentary
Blogs on Beraprost
Definitions
Definitions of Beraprost
Patient Resources / Community
Patient resources on Beraprost Discussion groups on Beraprost Patient Handouts on Beraprost Directions to Hospitals Treating Beraprost Risk calculators and risk factors for Beraprost
Healthcare Provider Resources
Symptoms of Beraprost Causes & Risk Factors for Beraprost Diagnostic studies for Beraprost Treatment of Beraprost
Continuing Medical Education (CME)
CME Programs on Beraprost
International
Beraprost en Espanol Beraprost en Francais
Business
Beraprost in the Marketplace Patents on Beraprost
Experimental / Informatics
List of terms related to Beraprost

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical pharmacology

As an analogue of prostacyclin PGI₂, beraprost effects vasodilation, which in turn lowers the blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill.